Trial Profile

A study of Ivonescimab plus risvutatug rezetecan in solid tumor.

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 19 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

19 Feb 2026 New trial record
12 Jan 2026 According to Summit Therapeutics media release, The study is expected to begin dosing patients in mid-2026 and Under the terms of the agreement, Summit will supply ivonescimab for the planned study, while GSK will manage the day-to-day clinical operations of the study. Each party will maintain rights to their respective products, and the agreement is mutually non-exclusive.
12 Jan 2026 According to Summit Therapeutics media release, company announced it has entered into a clinical trial collaboration with GSK plc to evaluate ivonescimab, a novel, investigational in combination with risvutatug rezetecan GSKs novel investigational B7-H3 targeting antibody drug conjugate (ADC), across multiple solid tumor settings, including small cell lung cancer (SCLC).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com